Recent News for NBRV - Nabriva Therapeutics AG

Date Title
Oct 15 Nabriva to Present Data at the CHEST Annual Meeting Demonstrating the Safety and Efficacy of Newly FDA-Approved XENLETA (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Oct 11 3 ‘Strong Buy’ Biotech Stocks That Could Triple in 2020
Oct 3 Nabriva Therapeutics (NBRV) Presents At Cantor Healthcare Conference - Slideshow
Oct 3 12 Healthcare Stocks Moving In Thursday's Pre-Market Session
Oct 1 Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
Sep 27 Lefamulin Evaluation Against Pneumonia 2 (LEAP 2) Study Results Published in the Journal of the American Medical Association
Sep 26 Nabriva to Present Data from XENLETA (lefamulin) and CONTEPO (fosfomycin) Development Programs at IDWeek 2019
Sep 25 The Lowdown On Nabriva
Sep 18 Nabriva Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
Sep 11 Is Nabriva Therapeutics (NASDAQ:NBRV) Using Too Much Debt?
Sep 9 Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.
Sep 6 Nabriva receives $5M milestone payment from Sinovant Sciences
Sep 6 Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences
Aug 29 Nabriva Therapeutics Plc (NBRV) CEO Theodore R Schroeder Bought $89,500 of Shares
Aug 29 23 Healthcare Stocks Moving In Thursday's Pre-Market Session
Aug 28 Nabriva Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
Aug 25 The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend
Aug 21 A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019
Aug 21 Plus Therapeutics leads healthcare gainers; TrovaGene leads the losers
Aug 21 Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
Aug 20 Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
Aug 20 FDA Nods Fuel Unsual Options Volume on NBRV, MRNA
Aug 20 Nabriva Analysts Bullish After FDA OKs Antibiotic; BofA Sees $200M Sales Potential
Aug 20 SDRL, BIDU among premarket gainers
Back to the Main NBRV Page...